Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Immix Biopharma, Inc.

Get SEC filing alerts via email and in your feed for Immix Biopharma, Inc.

IMMX

Immix Biopharma, Inc.

About Immix Biopharma, Inc.

Immix Biopharma is a clinical-stage biopharmaceutical company developing innovative cell therapies, primarily CAR-T, for light chain (AL) Amyloidosis and immune-mediated diseases. Its lead candidate, NXC-201, targets relapsed/refractory AL Amyloidosis, with ongoing clinical trials and regulatory designations including Orphan Drug and RMAT. The company focuses on leveraging proprietary platforms to create accessible, targeted treatments for serious, underserved conditions.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Immix Biopharma, Inc.

1
1
Immix Biopharma, Inc. Immix Biopharma Reports $10.1 Million Net Loss in Q1 2026, Focuses on NXC-201 Development

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Immix Biopharma, Inc. Immix Biopharma Reports Increased Losses and Significant Asset Growth in 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Immix Biopharma, Inc. Immix Biopharma Reports $7.6 Million Net Loss in Q3 2025, Seeks Additional Funding

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Immix Biopharma, Inc. Immix Biopharma Reports Increased Net Loss and Rising Operating Expenses for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Immix Biopharma, Inc. Immix Biopharma Reports $4.54 Million Net Loss in Q1 2025, Highlights Clinical Advancements

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Immix Biopharma, Inc. Immix Biopharma Reports $21.7 Million Net Loss for 2024, Highlights Clinical Advancements

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Immix Biopharma, Inc. Immix Biopharma Reports Financial Results, Net Loss, and Strategic Developments in 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments